- Active not recruitingPHASE3
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)
This study is looking at a new combination of medicines, naporafenib and trametinib, for people with a specific type of advanced melanoma. It aims to see if this combination works better than standard treatments for patients whose melanoma has certain genetic changes and has progressed after other treatments.
For: Advanced or Metastatic NRAS-mutant MelanomaUnited States · Australia · Canada - Active not recruitingPHASE1
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations
This study is testing two medicines, Naporafenib and Trametinib, together for certain advanced cancers. It's for people whose cancer has a specific change called RAS Q61X, and who haven't responded to other treatments or have limited options.
For: Advanced or Metastatic Solid TumorsUnited States · Australia · Canada - Active not recruitingPHASE2
Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma
This study looks at two medicines, trametinib alone or with GSK2141795, for uveal melanoma that has spread. It wants to see which treatment works best to slow down or stop the cancer's growth.
For: Recurrent Uveal Melanoma · Stage IV Uveal Melanoma AJCC v7United States · France · United Kingdom - Active not recruitingPHASE4
Pediatric Long-Term Follow-up and Rollover Study
This study looks at the long-term well-being of children and young people who have been treated with specific medications (dabrafenib and/or trametinib) for certain brain cancers in previous clinical trials. It aims to understand the lasting effects of these treatments.
For: Diffuse Astrocytoma · Anaplastic Astrocytoma · AstrocytomaUnited States · Argentina · Australia - Active not recruitingPHASE2
Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma
This study is looking for new ways to treat advanced melanoma, a type of skin cancer. It's testing combinations of new medicines (LXH254, LTT462) with existing ones (Trametinib, Ribociclib) in people whose melanoma has progressed after previous treatments. The goal is to see how well these new combinations work and if they are safe.
For: MelanomaUnited States · Argentina · Australia - RecruitingPHASE1, PHASE2
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
This study looks at new drug combinations for multiple myeloma that has come back or isn't responding to usual treatment. It checks how safe they are, body reactions, and early signs of how well they might work.
For: Multiple MyelomaUnited States · Canada · Norway - RecruitingPHASE1, PHASE2
HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies
This study looks at new drug combinations for children and young adults with blood cancers (leukaemia and lymphoma) that have come back or not responded to treatment. It focuses on cancers with specific genetic changes, hoping to find safer and more effective ways to help them.
For: Acute Lymphoblastic Leukemia, in Relapse · Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent · Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) RecurrentAustria · Belgium · Denmark - RecruitingPHASE2
Pan Tumor Rollover Study
This study looks at the long-term safety of different cancer treatments, including nivolumab, alone or combined with other medicines. It's for people with various types of cancer who are already receiving treatment in a related study, aiming to see how these treatments work over time.
For: CancerUnited States · Argentina · Australia - Active not recruitingPHASE2
Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway.
This study looks at a medicine called trametinib for children and young people (aged 1 month to 25 years) with certain brain tumours or nerve tumours that haven't responded to other treatments. It aims to see how well the medicine works and understand more about these conditions.
For: Low-grade Glioma · Plexiform Neurofibroma · Central Nervous System GliomaCanada - Active not recruitingPHASE1
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
This study is looking into new ways to treat advanced cancers that have a specific genetic change called KRAS p.G12C. It's testing a drug called sotorasib, either by itself or with other treatments, to see how safe and effective they are for adults.
For: Advanced Solid Tumors · Kirsten Rat Sarcoma (KRAS) pG12C MutationUnited States · Australia · Austria - Not yet recruitingPHASE2, PHASE3
DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
This study looks at two drugs called dabrafenib and trametinib for various cancers with a specific gene change (BRAF V600). These drugs are already approved for some cancers and researchers want to see if they can help people with other rare cancers or cancers with this same change.
For: Haematological Malignancy · Malignant Neoplasm · Lymphoproliferative DisordersUnited Kingdom - RecruitingPHASE2
Pediatric Low Grade Glioma - MEKinhibitor TRIal vs Chemotherapy
This study is looking at a new medicine called Trametinib for children and young adults with a specific type of slow-growing brain tumour called low-grade glioma. It compares Trametinib to a standard treatment, Vinblastine, to see if it works better at stopping the tumour from growing.
For: Grade 1 Glioma · Mixed Glio-neuronal Tumors · Pleomorphic XanthoastrocytomaFrance - Active not recruitingPHASE3
Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer
This study is testing if two drugs, dabrafenib and trametinib, can help people with a specific type of thyroid cancer (DTC) that has a BRAF V600E gene change, has stopped responding to radioactive iodine, and has progressed after other treatments.
For: Differentiated Thyroid Cancer (DTC)United States · Argentina · Brazil - RecruitingPHASE4
Dabrafenib and/or Trametinib Rollover Study
This study allows patients already on dabrafenib and/or trametinib for certain cancers to continue treatment if their doctor thinks it's helping and they meet specific criteria. It's for people already in another study.
For: Melanoma · Non Small Cell Lung Cancer · Solid TumorUnited States · Argentina · Austria - Active not recruitingPHASE1
A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation)
This study is for adults with advanced cancer that has a specific change called a KRAS mutation. It tests new doses of a medicine called BI 1701963, given alone or with another drug, trametinib. The goal is to find safe doses and see if they can shrink tumours.
For: Solid Tumors, KRAS Mutation; SOS1United States · Germany · Netherlands